Clinical Trials on Prostatic Intraepithelial Neoplasia

Total 107730 results

AstraZeneca

Completed

Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer (AZD2171IL/0003)

Advanced Prostate Adenocarcinoma

United States
Sanofi

Terminated

Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer

Metastatic Prostate Cancer

Brazil
Cytogen Corporation

Unknown

Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer (CYT-500)

Metastatic Prostate Cancer

United States
AstraZeneca

Withdrawn

CMAB vs IMAB in Metastatic Prostate Cancer

Metastatic Prostate Cancer

Mexico
Albert DeNittis

Unknown

Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer

Prostate Neoplasms

United States
University of Chicago

Active, not recruiting

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
University Hospital Tuebingen

Recruiting

Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma (ZGynO_CINIII)

Cervical Intraepithelial Neoplasia III

Germany
Novartis Pharmaceuticals

Completed

Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases

Prostate Cancer
European Institute of Oncology

Recruiting

Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens

Anal Cancer | High-Risk Cancer | Anal Intraepithelial Neoplasia 2 | Anal Intraepithelial Neoplasia 1

Italy
University of Washington
National Cancer Institute (NCI)

Completed

Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening

Cervical Carcinoma | Human Papillomavirus Infection | Health Status Unknown | Cervical Intraepithelial Neoplasia Grade 2/3 | Stage 0 Cervical Cancer | Atypical Squamous Cell of Undetermined Significance | Low Grade Cervical Squamous Intraepithelial Neoplasia

United States
National Cancer Institute (NCI)

Enrolling by invitation

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Prostate Cancer | Neoplasms of Prostate | Cancer Of Prostate | Prostate Neoplasms | Prostatic Cancer

United States
University Health Network, Toronto

Active, not recruiting

Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR (PSMA-DOCS)

Neoplasm, Prostate

Canada
University of Southern California
National Cancer Institute (NCI); National Institute for Biomedical Imaging...

Terminated

18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

Prostate Neoplasm

United States
Sanjay Gupta PhD

Terminated

Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer

Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Mayo Clinic

Completed

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Millennium: The Takeda Oncology Company

Completed

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Terminated

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Rennes University Hospital

Completed

Evaluation of the Potential Association Between 5α-reductase Inhibitors Prescription and Occurrence of High Grade Prostate Cancers (CANARI)

Benign Prostate Hyperplasia

France
National Cancer Institute (NCI)

Completed

Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer

Recurrent Prostate Cancer | Bone Metastases | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
I.M. Sechenov First Moscow State Medical University
Pirogov Russian National Research Medical University; Moscow Regional Research...

Recruiting

Active Surveillance for Low Risk Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma

Russian Federation
Advocate Health Care

Recruiting

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

Prostate Adenocarcinoma

United States
Centre Hospitalier Universitaire de Saint Etienne
National Cancer Institute, France

Completed

Physical Activity Experiment on Male Prostate Cancer Patients (ACTI_PAIR)

Cancer Prostate

France
University of Utah
Genentech, Inc.; Bavarian Nordic

Withdrawn

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)

Prostate Adenocarcinoma

United States
Chang Gung Memorial Hospital

Unknown

Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer (PCAPETMR)

Prostate Adenocarcinoma

Taiwan
Fundacao Champalimaud

Completed

Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer (PROSINT)

PROSTATE CANCER

Portugal
Rennes University Hospital
Center Eugene Marquis

Completed

Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers (TARGET)

Prostate Cancer | Prostate Adenocarcinoma

France
M.D. Anderson Cancer Center
Celgene

Completed

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

Prostate Cancer

United States
University of California, Irvine

Withdrawn

Imaging of Prostate Cancer Using Two-dimensional MR Spectroscopy and Diffusion Tensor Imaging

Prostate Lesions

United States
VA Office of Research and Development
Sanofi

Completed

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma (CAP)

Prostate Cancer

United States, Puerto Rico
University College London Hospitals

Completed

Prostate Cancer Genomic Heterogeneity (PROGENY)

PROSTATE CANCER

United Kingdom
GenSpera, Inc.

Withdrawn

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer.

United States
Genzyme, a Sanofi Company

Completed

Trilostane for Androgen-Independent Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma

United States
SCRI Development Innovations, LLC
Bristol-Myers Squibb

Completed

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

Prostate Cancer
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...
National Research Council

Recruiting

Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression (OBESITA'&PCa)

Obesity | Prostate Cancer | Prostate Adenocarcinoma | Prostate Neoplasm | Prostatic Neoplasm

Italy
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Terminated

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Colorado, Denver
EDAP TMS S.A.

Completed

The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute

Completed

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of California, Irvine
Bristol-Myers Squibb

Completed

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer (EASE)

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Azienda Socio Sanitaria Territoriale degli Spedali...
Takeda

Unknown

PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation. (PRO-EPI)

Intermediate Risk Prostate Cancer | High Risk Prostate Cancer

Italy
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States

Clinical Trials on Prostatic Intraepithelial Neoplasia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations